We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group
Background : The purpose of this study was to evaluate gemcitabine – carboplatin ( GCb ) versus single-agent gemcitabine ( G ) in patients with advanced non-small cell lung cancer ( NSCLC ) and a performance status ( PS ) of 2 . The primary endpoint was clinical benefit . Patients and Methods : Patients were r and omly assigned to either 1250 mg/m2 of G ( arm A ) or 1250 mg/m2 of G plus carboplatin area under the curve of 3 ( arm B ) . Both treatments were given on days 1 and 14 and were repeated every 28 days for up to four cycles . Results : Among the 90 eligible patients ( 47 in arm A and 43 in arm B ) , in arm A , two ( 4 % ) had partial responses ( 95 % CI , 0.52%–14.5 % ) and 10 ( 21 % ) had stable disease ( 95 % CI , 10.7%–35.7 % ) . In arm B , six ( 14 % ) had partial responses ( 95 % CI , 5.3%–27.9 % ) and nine ( 21 % ) had stable disease ( 95 % CI , 10%–36 % ) ( p = 0.14 ) . No significant difference was found in terms of clinical benefit between the two treatment groups after two cycles of treatment or at the end of chemotherapy . Furthermore , no association was found between clinical benefit and response to treatment ( p > 0.05 ) . Median survival was 4.8 months ( 95 % CI , 2.45–7.25 ) for arm A and 6.7 months ( 95 % CI , 2.47–10.8 ) for arm B ( p = 0.49 ) . Neutropenia ( p = 0.007 ) and thrombocytopenia ( p < 0.001 ) were more common in group B. Nevertheless , no significant differences were found in terms of severe toxicities ( p > 0.05 in all cases ) . Conclusion : No significant difference was found in terms of clinical benefit in patients with NSCLC and PS 2 who received single-agent G or GCb . Nevertheless , GCb caused more toxicity , particularly neutropenia and thrombocytopenia
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV